The effectiveness of teriparatide in the clinical practice-attenuation of the bone mineral density outcome by increasing age and bisphosphonate pretreatment

Annals of Medicine

Volumn 45, Issue 3, 2013, Pages 230-235

  Koski, Anna Mari ^a   Löyttyniemi, Eliisa ^b   Väänänen, Hannu ^c   Laine, Hanna ^d   Niskanen, Leo ^e   Nevalainen, Pasi I ^f   Korpi Hyövälti, Eeva ^g   Välimäki, Matti J ^h  

^a JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c ORTON ORTHOPAEDIC HOSPITAL   (Finland)

^d Pulssi Medical Center   (Finland)

^e UNIVERSITY OF EASTERN FINLAND   (Finland)

^f TAMPERE UNIVERSITY HOSPITAL   (Finland)

^g SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Back pain; Bisphosphonate; Bone mineral density; Osteoporosis; Teriparatide

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CORTICOSTEROID; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; ZOLEDRONIC ACID;

ADULT; AGED; AGING; ANALGESIA; ANKLE FRACTURE; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE TURNOVER; CLINICAL PRACTICE; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FEMUR NECK; FRAGILITY FRACTURE; HEART ATRIUM FIBRILLATION; HIP; HIP FRACTURE; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERTENSION; HYPOTENSION; INJECTION SITE IRRITATION; LEG PAIN; LUMBAR SPINE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYALGIA; NAUSEA; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SPINE FRACTURE; URTICARIA;

ABSORPTIOMETRY, PHOTON; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; BACK PAIN; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; FEMUR NECK; HIP JOINT; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PEPTIDES; PROCOLLAGEN; RETROSPECTIVE STUDIES; TERIPARATIDE;

EID: 84876152381     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2012.742560     Document Type: Article

References (24)

1. Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OL, Courpron P, et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J.;280:1340-4.
2. Bradbeer JN, Arlot ME, Meunier PJ, Reeve J. Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone. Clin Endocrinol (Oxf). 1992;37:282-9.
3. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EE Recombinant human parathyroid hormone (1 -34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003;18:1932-41. (Pubitemid 37377441)
4. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich G A, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344 : 1434-41. (Pubitemid 32402100)
5. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, et al. Thie effect of teriparatide [human parathyroid hormone(1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003; 18 : 9-17. (Pubitemid 36008334)
6. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest. 1998;102:1627-33. (Pubitemid 28492231)
7. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007; 357 : 2028-39. (Pubitemid 350106710)
8. Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2005; 1? : 510.
9. Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, et al. Effects of teriparatide versus alendronate for treating glucocorticoid- induced osteoporosis: thirty-six-month results of a randomized, doubleblind, controlled trial. Arthritis Rheum. 2009 ; 60 : 334?-55.
10. Marcus R, Wang O, Satterwhite J, Mitlak B. Thie skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res. 2003; 18 : 18-23. (Pubitemid 36008335)
11. Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc. 2007 ; 54 : 782-9.
12. Schwarz P, Jorgensen NR, Mosekilde L, Vestergaard P. Effects of increasing age, dosage, and duration of PTH treatment on BMD increase-a meta-analysis. Calcif Tissue Int. 2012;90:165-73.
13. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003 ; 349 : 121?-2.
14. Finkelstein JS, Wyland JJ, Lee H, Neer RM. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010;95:1838-45.
15. Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 2004;19:745-51. (Pubitemid 41094385)
16. Middleton ET, Steel SA, Doherty SM. Thie effect of prior bisphosphonate exposure on the treatment response to teriparatide in clinical practice. Calcif Tissue Int. 2007; 81 : 335-40. (Pubitemid 350077202)
17. Keel C, Kraenzlin ME, Kraenzlin CA, Muller B, Meier C. Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice. J Bone Miner Metab. 2010; 28: 8-287.
18. Koski AM, Sikiö A, Forslund T. Teriparatide treatment complicated by malignant myeloma. BMJ Case Rep. 2010; doi:10.1136/bcr.01. 2010.2?81.
19. Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res. 2008;23: 1591.
20. Finkelstein JS, Leder BZ, Burnett SM, Wyland JJ, Lee H, de la Paz AV, et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab. 2000 ; 91 : 2882-7.
21. Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab. 2008; 93 : 3785-93.
22. Boonen S, Marin F, Obermayer-Pietsch B, Simoes ME, Barker C, Glass EV, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab.; 93 : 852.
23. Miller PD, Shergy WJ, Body JJ, Chen P, Rohe ME, Krege JH. Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. J Rheumatol. 2005;32: 155-2.
24. Miller PD, Bilezikian JP, Diaz-Curiel M, Chen P, Marin F, Krege JH, et al. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab. 2007;92:3535-41. (Pubitemid 47435332)